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Early co-occurrence of a neurologic-psychiatric
disease pattern in Niemann-Pick type C disease:
a retrospective Swiss cohort study
Lucia Abela1,2,3*, Barbara Plecko1,2,3, Antonella Palla4, Patricie Burda2,5, Jean-Marc Nuoffer6, Diana Ballhausen7
and Marianne Rohrbach2,5
Abstract
Background: Niemann-Pick disease type C (NP-C) is a rare autosomal recessive disorder of lysosomal cholesterol
transport. The objective of this retrospective cohort study was to critically analyze the onset and time course of
symptoms, and the clinical diagnostic work-up in the Swiss NP-C cohort.
Methods: Clinical, biochemical and genetic data were assessed for 14 patients derived from 9 families diagnosed
with NP-C between 1994 and 2013. We retrospectively evaluated diagnostic delays and period prevalence rates for
neurological, psychiatric and visceral symptoms associated with NP-C disease. The NP-C suspicion index was
calculated for the time of neurological disease onset and the time of diagnosis.
Results: The shortest median diagnostic delay was noted for vertical supranuclear gaze palsy (2y). Ataxia, dysarthria,
dysphagia, spasticity, cataplexy, seizures and cognitive decline displayed similar median diagnostic delays (4–5y).
The longest median diagnostic delay was associated with hepatosplenomegaly (15y). Highest period prevalence
rates were noted for ataxia, dysarthria, vertical supranuclear gaze palsy and cognitive decline. The NP-C suspicion
index revealed a median score of 81 points in nine patients at the time of neurological disease onset which is
highly suspicious for NP-C disease. At the time of diagnosis, the score increased to 206 points.
Conclusion: A neurologic-psychiatric disease pattern represents the most characteristic clinical manifestation of
NP-C and occurs early in the disease course. Visceral manifestation such as isolated hepatosplenomegaly often fails
recognition and thus highlights the importance of a work-up for lysosomal storage disorders. The NP-C suspicion
index emphasizes the importance of a multisystem evaluation, but seems to be weak in monosymptomatic and
infantile NP-C patients.
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Background
Niemann-Pick disease type C (NP-C) is a rare autosomal
recessive disorder characterized by lysosomal cholesterol
transport abnormalities. NP-C has an estimated inci-
dence of 1:120′000 [1-4]. 95% of the NP-C patients har-
bor mutations in the NPC1 gene, while only 4% carry
mutations in the NPC2 gene [5]. NPC1 encodes a large
transmembrane glycoprotein [6] and NPC2 a smaller
soluble lysosomal protein, respectively [7]. Both proteins
are involved in the transport of intracellular cholesterol,
that derives from endocytosed LDL particles [8]. Dys-
function of these proteins leads to impaired intracellular
trafficking and accumulation of unesterified cholesterol in
lysosomes and late endosomes [9,10]. The lipid storage
pattern differs markedly in visceral and neural tissues
[11-14]. Liver and spleen mainly accumulate cholesterol
and other lipid compounds, while in brain tissue accumu-
lation of glycosphingolipids prevails [11,12,15]. Visceral
storage leads to early clinical symptoms including pro-
longed neonatal jaundice and isolated splenomegaly with
or without hepatomegaly [8]. Neuronal storage results in
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meganeurite formation and ectopic dendritogenesis, neu-
roaxonal dystrophy with demyelination and accumulation
of Alzheimer’s-like neurofibrillary tangles [8,15,16]. The
resulting neurological and psychiatric disease pattern is
quite heterogeneous [8,16,17], even though neurodegener-
ation seems to follow a distinct distribution pattern, first
affecting highly vulnerable neurons such as Purkinje cells
in the cerebellum [15]. The NP-C suspicion index tool
was developed in 2012 in order to help clinicians to better
identify patients at risk for NP-C disease [18]. Three clin-
ical categories including visceral, neurological and psychi-
atric symptoms are scored according to their relative
association with NP-C disease. Patients with a score >70
points should be referred for further testing. In recent
years, several reports have further improved the awareness
for NP-C disease and shed light on its natural history
[16,19-26]. With this retrospective study of the Swiss NP-
C cohort, we intend to better characterize the disease
manifestations in different age groups with a particular
focus on neurological and psychiatric symptoms.
Methods
Study design
The study presented here is an observational retrospect-
ive cohort study including all known Swiss NP-C pa-
tients. Seven patients of this cohort have been included
in a previous study and can be identified by their re-
spective patient ID in the legend of Table 1. Clinical data
were collected by retrospective analysis of all available
medical records, in particular visceral, neurological and
psychiatric symptoms. The observation period included
data from the onset of the first clinical symptom and
ended in September of 2013. NP-C disease was con-
firmed by either biochemical (filipin staining and choles-
terol esterification) and/or molecular analysis. Patients
were characterized into early-infantile (0–2 years), late-
infantile (2–6 years), juvenile (6–15 years) and adult
(>15 years), according to the age of neurological onset
[4]. Period prevalence rates of clinical symptoms, i.e. vis-
ceral, neurological or psychiatric, were calculated in age
groups of 5 to 20 years intervals, respectively. The
period prevalence rates of respective symptoms among
our cohort were calculated by the number of affected
patients divided by the total number of patients alive in
this age period. Data are presented in median ±2 stand-
ard deviations and the corresponding range. The NP-C
suspicion Index published in 2012 [18] was assessed
retrospectively for the time of neurological disease onset
and for the time of diagnosis. Scores at the time of
neurological disease onset are based on the information
available from the chart reports. For index patients, the
delay to diagnosis was defined as the time period be-
tween first recorded visceral, neurological or psychiatric
symptoms compatible with NP-C and the time of
diagnosis (biochemically and/or genetically defined). The
study was conducted in accordance with an approval of
the Local Ethics Committees granted to our institution
and valid until 31th of December 2013.
Biochemical and molecular analysis
Bone marrow histology and measurement of chitotriosi-
dase activity in plasma were performed as described and
included when available [27]. Filipin staining of cultured
fibroblasts was performed and interpreted as previously
described [28]. Cholesterol esterification assays were
performed by M. Vanier in two patients [28]. Molecular
analysis of NPC1 and NPC2 was performed in the Insti-
tute of Human Genetics in Heidelberg (Germany) and in
the Center for Molecular Diseases in the University Hos-
pital in Lausanne (Switzerland).
Ethical approval and consent
The study was conducted in accordance with an ap-
proval of the Local Ethics Committees granted to our in-
stitution and valid until 31th of December 2013. This
approval allows treating physicians to perform retro-
spective data evaluation without prior informed consent.
Results
Between 1994 and 2013, 14 patients derived from nine
non-consanguineous families were diagnosed with NP-
C. Two patients had late-infantile, eight patients a juven-
ile and four patients an adult-onset form of NP-C dis-
ease. Table 1 provides a detailed overview on clinical,
biochemical and genetic findings as well as age of treat-
ment initiation with Miglustat. Additional file 1: Table
S1 provides individual information on clinical symptoms
at neurological disease onset and at the time of
diagnosis.
Biochemical and genetic analysis
Filipin staining of cultured fibroblasts was clearly abnor-
mal in 11 patients, variant in two and unavailable in one
patient. Plasma chitotriosidase activity was elevated in
five patients, normal in seven and unavailable in two pa-
tients. Histology of bone marrow was available for eight
patients, all of whom showed sea blue histiocytes and/or
foam cells. Molecular analysis confirmed the diagnosis
in family 1, 2, 3 and 4 and in patient 5, 6 and 7. Patient
8 was diagnosed by positive filipin staining only. Patient
9 was diagnosed by abnormal cholesterol esterification
and abnormal filipin staining.
Clinical symptoms
Neurological symptoms
Documentation of neurological symptoms prior to diag-
nosis was available in nine patients only (1a, 2a/b, 3a,
4a/b, 6, 7, 8) with onset of symptoms ranging from of
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Table 1 Summary of clinical, biochemical and genetic patient data (n = 14)
Patient Sex Age at
diagnosis
Age at start
of treatment
New symptoms
under therapy
Age at
last visit
Subtype Chitotriosidase Filipin
staining
Cholesterol
esterification
Bone marrow Genetics (NPC1)
1a* m 30 31 - 33 Juvenile Normal Clearly
abnormal
na Sea blue histiocytes,
foam cells
p.Arg978Cys/delX1-X6
1b* f 27 28 Mild Polyneuropathy 30 Adult 9.9 mU/ml (0.0–4.6) Clearly
abnormal
na na p.Arg978Cys/delX1-X6
1c* f 22 22 - 24 Adult Normal Clearly
abnormal
na na p.Arg978Cys/delX1-X6
2a* f 15 30 (− 32) - †32 Juvenile 8.2 mU/ml (0.0–4.6) Clearly
abnormal
Abnormal Sea blue histiocytes,
foam cells
p.Pro474Leu/p.Ile1094Thr
2b* m 19 29 - 35 Juvenile Normal Clearly
abnormal
na Sea blue histiocytes,
foam cells
p.Pro474Leu/p.Ile1094Thr
3a m 15 - - 15 Juvenile Normal Variant na na p.Ser940Leu/p.Pro1007Ala
3b f 10 - - 10 Juvenile Normal na na na p.Ser940Leu/p.Pro1007Ala
4a* m 18 29 Dysphagia 29 Juvenile 11.3 mU/ml (0.3–3.7) Clearly
abnormal
na Sea blue histiocytes,
foam cells
p.Ile1061Thr/p.Ile1061Thr
4b* m 16 27 Dysphagia,
dystonia,
seizures
27 Juvenile 4.4 mU/ml (0.3–3.7) Clearly
abnormal
na Sea blue histiocytes,
foam cells
p.Ile1061Thr/p.Ile1061Thr
5 m 2 3 VSGP 5 Late-infantile 24.5 mU/ml (0.0–1.03) Variant na Sea blue histiocytes,
foam cells
p.Ile1067Thr/p.Asp948Asn
6 m 7.5 - - †7.5 Late-infantile na Clearly
abnormal
na Foam cells c.1554-1009G > A
(intron 9)/p.Tyr1081*
7 f 50 50 Dysphagia 51 Adult Normal Clearly
abnormal
na Sea blue histiocytes,
foam cells
p.Asp898Asn/ p.Pro1245Cysfs*12
8 f 23 24 - 25 Adult Normal Clearly
abnormal
na na na
9 f 15 - - †25 Juvenile na Clearly
abnormal
Abnormal na na
na: not available; †deceased, *Patients included in [23]: 1a > 044, 1b > 042, 1c > 043, 2a > 020, 2b > 021, 4a > 018, 4b > 019.
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three to 46 years. In this group, the median diagnostic
delay from the onset of the first recorded neurological
symptom to the diagnosis was 5 ± 12.4, range 4–21
years. Presenting neurological symptoms included ataxia
in six, dysarthria in two, spasticity in two, dystonia in
one, cataplexy in one, vertical nuclear gaze palsy (VSGP)
in one and seizures in one of nine patients. Three pa-
tients displayed a combination of neurological symp-
toms. At the time of diagnosis, ataxia was present in 13,
VSGP in 12, dysarthria in 11, spasticity in five, dystonia
in two and cataplexy in two of 14 patients. Median diag-
nostic delays of individual neurological symptoms were
calculated for index patients only (Figure 1). The shortest
median diagnostic delay is seen with VSGP (2 ± 2.0, range
1–3 years) while dysphagia (4 ± 5, range 2–7 years), sei-
zures (5 ± 4, range 3–7 years), ataxia (4 ± 13.1, range 2–21
years), dysarthria (4 ± 2.2, range 2–7 years), spasticity (4 ±
1.2, range 4–5 years) and cataplexy (4.8 ± 0.7, range 4.5–5
years) have similar medians of diagnostic delay. Dystonia
displays the longest diagnostic delay (9 ± 14.1, range 4–14
years), but was present only in two patients prior to
diagnosis.
Psychiatric symptoms
Four patients (1a, 3a, 4b, 9) exhibited behavioural distur-
bances before diagnosis: aggressive behaviour in patient
1a from the age of six years, social withdrawal and emo-
tional lability in patient 3a from the age of nine years,
emotional lability and absence-like episodes in patient
4b from the age of seven years and emotional lability in
patient 9 from the age of 14 years. Behavioural distur-
bances had a median diagnostic lag of 7 ± 18.5, range 1–
24 years (Figure 1). Out of these patients with documented
neurological onset prior to diagnosis, cognitive decline
was reported before or at the onset of neurological symp-
toms in six of nine patients. At the time of diagnosis, cog-
nitive decline was reported in 12 of 14 patients. The
median diagnostic delay of cognitive decline was 5 ± 28.8,
range 1–41 years (Figure 1). Patient 1a exhibited psychotic
episodes after the onset of neurological symptoms but
prior to diagnosis. Cognitive decline and recurrent de-
pressive/psychotic episodes were presenting symptoms
in patient 1b.
Visceral symptoms
Patient 8 and 9 presented with neonatal onset hepatos-
plenomegaly accompanied by prolonged neonatal jaun-
dice in the latter. Four patients (1a, 4a, 4b, 5) exhibited
splenomegaly during infancy at the age of four years,
two years, three years as well as six months, respectively.
Patient 7 underwent splenectomy at the age of 18 years.
Electron-microscopic analysis of spleen tissue revealed
sea blue histiocytes. The diagnosis of Niemann-Pick was
suspected. Additional biochemical analysis showed
slightly reduced activity of sphingomyelinase in fibro-
blasts, however, not in the range to diagnose Niemann-
Pick type A/B. Patient 7 was not further seen by specialists
and not diagnosed with NP-C until 32 years later. In pa-
tient 1b, 3a and 3b splenomegaly had only been recog-
nized at the time of diagnosis. Aside from patient 5 who
Figure 1 Neurological, psychiatric and visceral symptom onset in relation to diagnosis. Time interval from the onset of first recorded
neurological, psychiatric and visceral symptoms to the diagnosis. Time at diagnosis = 0. The first number in brackets represents patients with
symptom onset before diagnosis and includes index patients only. The second number represents the total patient number. Abbreviations: Del.
milest. = delayed milestones; Cog. decline = cognitive decline; Psych. symptoms = psychotic symptoms; Behav. probl. = behavioural problems;
Hep-spl.meg. = Hepatosplenomegaly; Prolong. jaund. = prolonged jaundice.
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was diagnosed with NP-C disease at the age of two years
based on his visceral manifestation, the remaining patients
(1a, 4a, 4b, 8, 9) were diagnosed only when neurological
symptoms emerged. In those with previously known
(hepato-)splenomegaly, the median diagnostic delay was
15.5 ± 23.2, range 1.5–32 years (Figure 1).
Intrafamilial heterogeneity
To highlight the intrafamilial heterogeneity, we subse-
quently provide details on disease onset and the clinical
course of families with several affected siblings.
Family 1
Patient 1a presented with ataxia and cognitive decline
from the age of 9 years. He developed dystonia and
dystonic-athetoid movement disorder in the second dec-
ade and suffered dysphagia, rare psychotic episodes and
seizures in the third decade, respectively. He was investi-
gated for Chorea Huntington, Morbus Wilson, syphilis,
neuroborreliosis, HIV, systemic lupus erythematodus,
Vitamin B12 and folinic acid deficiency and thyroid disor-
ders before the diagnosis of NP-C was made at the age of
30 years. Patient 1b had suffered from sensorineural hear-
ing loss from the age of 9 years. In the late second decade,
she developed cognitive decline. She presented with sev-
eral depressive and psychotic episodes from the age of
24 years and was diagnosed with mild ataxia and dysarth-
ria in the third decade. She was tested for subacute
sclerosing panencephalitis, syphilis, HIV, cerebrotendinous
xanthomatosis and mitochondrial cytopathies before she
was diagnosed with NP-C at the age of 27 years. Patient
1c was only diagnosed by pedigree analysis at the age of
22 years. She suffered progressive hearing loss from the
age of 18 years. During adolescence she had exhibited very
mild cognitive decline and was found with VSGP with de-
layed vertical saccades at the time of diagnosis.
Family 2
Patient 2a presented with ataxia, spasticity, VSGP and
cognitive decline at the age of 12 years. She was investi-
gated for metachromatic leukodystrophy before she was
diagnosed with NP-C at the age of 15 years. In the third
decade, she experienced a rapid progression with severe
dysarthria, dysphagia, ataxia, tetraspasticity and hyper-
kinetic movement disorder. She deceased at the age of
32 years. Patient 2b displayed VSGP, dysarthria and cog-
nitive decline at the age of 19 years. In the third decade,
he exhibited a slowly progressing course with ataxia,
dysphagia, a first psychotic episode and mild demyelinat-
ing polyneuropathy.
Family 3
Patient 3a suffered from an early disease onset with cata-
plexy and cognitive decline from the age of nine years.
In the second decade, he showed a progressive course with
VSGP, ataxia, dysphagia, seizures and dementia. Before the
diagnosis of NP-C was made at the age of 15 years, he was
investigated for adrenoleukodystrophy, metachromatic
leukodystrophy and Gaucher disease. Patient 3b was only
diagnosed by pedigree analysis at the age of ten years. She
exhibited splenomegaly, VSGP, ataxia and mild cognitive
decline until the last clinical visit at the age of 11 years.
Family 4
Patient 4a and 4b were found to have splenomegaly at
the age of 2 and 3 years. Patient 4b was misdiagnosed
with Gaucher disease at the age of five and a half years.
Treatment for Gaucher disease was not started due to
isolated hepatosplenomegaly. Both patients were re-
evaluated due to ataxia, spasticity and VSGP and cor-
rectly diagnosed with NP-C at the age of 16 and 18 years,
respectively. In the third decade, patient 4a exhibited
mild spasticity, dysphagia and mild cognitive decline,
while patient 4b showed a progressive course with dys-
tonia, dysphagia, spasticity, psychotic episodes, seizures
and cognitive decline.
Period prevalence rates of clinical symptoms in the
study cohort
Figure 2 illustrates the period prevalence rates of neuro-
logical, psychiatric and visceral symptoms for the respect-
ive age periods in our cohort. Developmental milestones,
hypotonia and cataplexy have been excluded from the
neurological part and prolonged jaundice from the visceral
part of the figure, respectively. These symptoms occurred
in only one or two of our patients in early childhood
(Additional file 1: Table S1) and did not show a longtime
evolution. Decreases in the period prevalence rates of dys-
tonia, behavioural disturbances and hepatosplenomegaly
are caused by either death or dropouts due to age. Infor-
mation on the beginning of treatment is not considered in
this figure. Five patients presented new symptoms under
treatment (Table 1), none of the existing symptoms were
reversible under treatment.
NP-C suspicion index
Figure 3 demonstrates the NP-C suspicion index score at
the time of neurological disease onset (N) and at the time
of diagnosis (D). The median score at neurological disease
onset in nine patients (including affected siblings) was 81 ±
76.2, range 65–156 points. All of these patients had a highly
suspicious score (≥70 points). At the time of diagnosis, the
median score was 206 ± 92, range 105–262 points in 13
patients. Patient 5 was excluded from indexing as the
neurological disease onset was after diagnosis. In four
patients (patient 1b, 1c, 3b, 9), it was not possible to evalu-
ate the onset of neurological symptoms based on the med-
ical records available.
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Discussion
Diagnosis of NP-C disease still poses a considerable
challenge to clinicians, hampered by the lack of specific
biomarkers and a remarkable inter- and intrafamilial
heterogeneity. In order to critically analyze the onset of
symptoms and clinical diagnostic work-up of NP-C dis-
ease, we retrospectively evaluated the Swiss cohort of 14
patients from nine families that have been diagnosed
with NP-C between 1994 and 2013. 12 patients had mu-
tations of the NP-C1 gene, while in two patients the
diagnosis of NP-C rested on abnormal filipin staining
and cholesterol esterification. Genotype-phenotype cor-
relation is limited in our group, as most of the patients
that underwent genetic analysis were compound hetero-
zygous. Intrafamilial heterogeneity was marked in family
1 in terms of onset and characteristics of symptoms. The
other families described here differed from each other in
the course of progression. Visceral symptoms preceded
neurologic or psychiatric symptoms in six patients irre-
spective of the age of onset. In two juvenile and one
adult patient, visceral symptoms were only recognized at
the time of diagnosis, which is in line with published data
in adult patients [20,22]. This stresses the importance of
including lysosomal storage diseases in the work-up of
isolated hepatosplenomegaly. In addition, it emphasizes
the importance of searching for organomegaly in neuro-
logic or psychiatric disorders of unclear etiology [18].
Psychiatric symptoms preceded neurological onset in
the form of cognitive decline in six and behavioural
problems in four of those nine patients where docu-
mentation provided exact age at neurological disease
onset. Nevertheless, psychiatric symptoms, though rec-
ognized, were only taken into account at the time of
first neurological assessment.
Cognitive decline may be difficult to recognize in
early disease stages [8]. Poor school performance, learning
disabilities, expressive language disorder and attention
deficit-hyperactivity have been described in late-infantile
and juvenile-onset patients [8,17,21,25] while more spe-
cific symptoms such as dysexecutive syndrome, reduced
processing speed and memory impairment occur later
[22,26]. Data from the international NP-C disease registry
show that cognitive impairment is one of the most consis-
tent finding across all age-at-onset categories [24]. Within
our patient cohort, cognitive decline was present in a total
13 of 14 patients at some point of disease.
(See figure on previous page.)
Figure 2 Presentation of clinical symptoms in terms of period prevalence rates in the study cohort. Age periods are represented in 5 to
20 years intervals on the x-axis. The period prevalence rates (%) were calculated for each clinical symptom by the number of affected patients in
the respective age period divided by the total number of patients alive in this period. The total patient number is represented in brackets for each
age period on the x-axis.
Figure 3 Comparison of the NP-C suspicion index at neurological disease onset (N) and at diagnosis (D). The NP-C suspicion index score
was calculated in nine patients at the time of documented neurological disease onset (N) and in 13 patients at the time of diagnosis (D). The
dotted line represents the cut-off of 70 points indicating high suspicion for NP-C disease. Combination categories include neurological/psychiatric,
visceral/neurological and visceral/psychiatric scores.
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Cerebellar and brainstem signs such as ataxia, dysarth-
ria and VSGP were the most common and earliest
neurological features in our cohort and were followed by
spasticity, dystonia and dysphagia after a median disease
course of five to ten years. VSGP displayed high period
prevalence rates, but in nine patients was only detected
at the time of diagnosis. Our findings in nine patients
with verifiable neurological disease onset show, that NP-C
most commonly manifests with neurologic-psychiatric
disease pattern (4/9 patients) and a neurological-
psychiatric-visceral pattern (4/9 patients) followed by a
visceral-neurological pattern (1/9 patients). Those findings
are in line with the existing natural history studies
[19,21,24,25]. A retrospective evaluation of a cohort of 38
patients revealed that cognitive and coordination deficits
are early disease indicators thus supporting our findings
[23]. Nevertheless, a neurological-psychiatric disease pat-
tern is not specific for NP-C disease.
Among our cohort, visceral symptoms had the highest
median diagnostic delay (15.5 ± 23.2 years). Cerebellar and
brainstem symptoms such as ataxia (4 ± 13.1 years), dys-
arthria (4 ± 2.2 years) and dysphagia (4 ± 5 years) had me-
dian diagnostic delays similar to cognitive decline (5 ±
28.8 years). The same delays were noted for the rarer
symptoms cataplexy (4.8 ± 0.7 years), seizures (5 ± 4 years)
and spasticity (4 ± 1.2 years). The shortest median diag-
nostic delay was observed for VSGP (2 ± 2.0 years), indi-
cating that this symptom may be more easily associated
with NP-C disease. To assess the diagnostic impact of the
NP-C prediction score, we retrospectively calculated the
score at the time of diagnosis and found a median score of
206 ± 92 points. At time of neurological disease onset,
retrospective calculation gave an estimate of 81 ± 76.2
points (>70 points suggesting high suspicion), but for
these patients, the median diagnostic delay was still 5 ±
12.4 years. This is in line with a larger survey from the
international NP-C disease registry [24]. The NP-C sus-
picion index tool was recently analyzed by ROC analysis
[29], showing that visceral manifestation had the weak-
est and neurological symptoms the highest discrimin-
atory power in juvenile and adolescent patients. In
infantile patients (<4 years), the discriminatory per-
formance was very poor. To overcome these problems,
a revised NP-C suspicion index with an improved pre-
dictive ability and an index for paediatric patients have
been developed recently [30,31].
Conclusion
Thus, especially in infantile patients, a work-up of iso-
lated hepatosplenomegaly has to include lysosomal stor-
age disorders such as Gaucher disease but also NP-C. In
juvenile and adolescent patients, we emphasize that co-
occurrence of neurological symptoms and cognitive de-
cline occurs early.
Limitations
This study is based on careful extraction of all available
data in the patient charts. This might constitute a poten-
tial weakness of the current study.
Additional file
Additional file 1: Table S1. Overview on neurological, visceral and
psychiatric symptoms at age of neurological disease onset (N) and at age
of diagnosis (D).
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